Iraterone acetate is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (previously called hormone-resistant or hormone-refractory prostate cancer) - i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists.